Lack of Association of SULT1A1 R213H Polymorphism with Colorectal Cancer: A Meta-Analysis

Chun Zhang1,2*, Jian-Ping Li1,*, Guo-Qiang Lv1, Xian-Min Yu1, Yuan-Long Gu1, Ping Zhou2*

1 Department of General Surgery, The Third Affiliated Hospital to Nantong University, Wuxi, China, 2 Intensive Care Unit, The Third Affiliated Hospital to Nantong University, Wuxi, China

Abstract

Background: A number of case-control studies were conducted to investigate the association of SULT1A1 R213H polymorphisms with colorectal cancer (CRC) in humans. But the results were not always consistent. We performed a meta-analysis to examine the association between the SULT1A1 R213H polymorphism and CRC.

Methods and Findings: Data were collected from the following electronic databases: PubMed, Elsevier Science Direct, Excerpta Medica Database, and Chinese Biomedical Literature Database, with the last report up to September 2010. A total of 12 studies including 3,549 cases and 5,610 controls based on the search criteria were involved in this meta-analysis. Overall, no significant association of this polymorphism with CRC was found (H versus R: OR = 1.04, 95%CI = 0.94–1.16, P = 0.46; HR versus RR: OR = 1.01, 95%CI = 0.92–1.11, P = 0.81; HH versus RR+HR: OR = 1.01, 95%CI = 0.74–1.38, P = 0.95; HH versus RR: OR = 1.00, 95%CI = 0.77–1.31, P = 0.98; HR versus RR: OR = 1.01, 95%CI = 0.92–1.11, P = 0.86). In subgroup analysis, we also did not find any significant association in Caucasians (H versus R: OR = 1.02, 95%CI = 0.92–1.15, P = 0.68; HR+HH versus RR: OR = 0.99, 95%CI = 0.91–1.09, P = 0.90; HH versus RR+HR: OR = 1.01, 95%CI = 0.73–1.39, P = 0.97; HH versus RR: OR = 0.99, 95%CI = 0.75–1.31, P = 0.94; HR versus RR: OR = 0.99, 95%CI = 0.90–1.09, P = 0.85). The results were not materially altered after the studies which did not fulfill Hardy-Weinberg equilibrium were excluded (H versus R: OR = 1.06, 95%CI = 0.95–1.19, P = 0.31; HR+HH versus RR: OR = 1.03, 95%CI = 0.93–1.13, P = 0.56; HH versus RR+HR: OR = 1.10, 95%CI = 0.78–1.56, P = 0.57; HH versus RR: OR = 1.09, 95%CI = 0.83–1.44, P = 0.53; HR versus RR: OR = 1.02, 95%CI = 0.92–1.13, P = 0.75).

Conclusion: This meta-analysis demonstrates that there is no association between the SULT1A1 R213H polymorphism and CRC.

Introduction

Colorectal cancer (CRC) is cancer of the colon or rectum, and it is equally common in men and women. With 655,000 deaths worldwide per year, it is the third leading cause of cancer-related death in the world [1,2]. In 2010, there were 142,570 new CRC cases and 51,370 deaths from CRC in the United States [2]. Currently, CRC is a major public health burden in many countries. Thus an understanding of the causes of this disease is an area of intense interest. Current evidence supports an important role for genetics in determining risk for CRC [3].

Sulfotransferases (SULTs) play an important role in normal physiological process and malignant transformation [4]. In humans, there are three members of the phenol sulfotransferase family (SULT1A1, SULT1A2, and SULT1A3). SULT1A1 is expressed in the liver as well as in many extrahepatic tissues including colonic mucosa, and is an component in the detoxification pathway of numerous xenobiotics [5,6]. It plays an important role in the metabolism and bioactivation of many dietary and environmental mutagens, including heterocyclic amines implicated in carcinogenesis of colorectal and other cancers [7,8]. Hence, SULT1A1 gene may be a good candidate for genetics studies on CRC.

The SULT1A1 gene is located on chromosome 16p12.1-p11.2 [9]. A polymorphism (R213H) in the SULT1A1 gene has been identified in the coding region at nucleotide 638 (a G to A transition). This base change results in a change in the amino acid sequence from arginine to histidine (Arg213His), leading to a decrease in enzymatic activity [10]. Since its discovery in 1997, this polymorphism has attracted widespread attention, and a number of case-control studies were conducted to investigate the association of this polymorphism with CRC in humans [11–24]. But the results are not always consistent. There are several possible explanations for this discordance, such as small sample size, ethnic background, uncorrected multiple hypothesis testing, and publication bias. Meta-analysis is a statistical procedure for combining the results of several studies to produce a single estimate of the major effect with enhanced precision [25]. It has become important in cancer genetics because of rapid increases in the number and size of datasets. The aim of
the present study is to perform a comprehensive meta-analysis to evaluate the association between the SULT1A1 R213H polymorphism and CRC.

Methods

Search strategy

In this meta-analysis, we performed an exhaustive search on studies that examined the association of the SULT1A1 gene polymorphisms with CRC. Data were collected from the following electronic databases: PubMed, Elsevier Science Direct, Excerpta Medica Database (Embase), and Chinese Biomedical Literature Database (CBM). We searched the articles using the search terms “sulfotransferase”, “SULT”, “SULT1A1”, “colorectal”, “colon”, “rectum”, and “colorectum”. Additional studies were identified by a hand search of references of original studies and review articles on the association between the SULT1A1 R213H polymorphism and CRC. No language restrictions were applied. A study was included in the current meta-analysis if (1) it was published up to September, 2010; (2) it was a case-control study of the SULT1A1 R213H polymorphism and CRC. We excluded the study in which family members were studied. When there were multiple studies from the same population, only the largest study was included.

Furthermore, two investigators independently searched the electronic databases. An independent PubMed search was done (by Zhou P and Zhang C) with the same method. An independent Elsevier Science Direct search was done (by Lv GQ and Yu XM) with the same method. An independent Embase search was done (by Gu YL and Li JP) with the same method. An independent CBM search was done (by Lv GQ and Yu XM) with the same method. References in original studies and review articles were reviewed (by Gu YL and Li JP) to identify additional studies.

Data extraction

Two investigators (Zhou P and Zhang C) independently extracted data and reached consensus on the following characteristics of the selected studies: the first author’s name, year of publication, source of publication, ethnicity, number of cases and controls, and available allele and genotype frequencies information. If original data was unavailable in articles, a request for original data was sent to the corresponding author.

Statistical analysis

The strength of association between the SULT1A1 R213H polymorphism and CRC was accessed by calculating odds ratio (OR) with 95% confidence interval (CI). We evaluated the allele contrast (H versus R), the codominant model (HH versus RR, HR versus RR), the dominant model (HR+HH versus RR) and the recessive model (HH versus RR+HR), respectively. The heterogeneity between the studies was assessed by the Chi square-test based Q-statistic [26]. A significant Q-statistic (P<0.10) indicated heterogeneity across studies. We also measured the effect of heterogeneity by another measure, I² = 100 × Q-df/Q [27]. The pooled OR was calculated by a fixed effect model (using the Mantel-Haenszel method) or a random effect model (using the DerSimonian-Laird method) according to the heterogeneity among studies [28,29]. The potential publication bias was estimated using Egger’s linear regression test by visual inspection of the Funnel plot [30]. In addition, a Chi square-test was used to determine if observed frequency of genotype in control population conformed to Hardy-Weinberg equilibrium (HWE) expectations. Analyses were performed using the software Review Manager 4.2 (Cochrane Collaboration, http://www.cc-ims.net/RevMan/relnotes.htm/) and Stata version 10 (StataCorp LP, College Station, Texas, USA). A P value less than 0.05 was considered statistically significant, and all the P values were two sided.

Results

Characteristics of eligible studies

Characteristics of studies included in the current meta-analysis are presented in Table 1 [11–22]. There were 2619 papers relevant to the searching terms (PubMed: 139; Elsevier Science Direct: 2220; Embase: 230; CBM: 30). The study selection process is shown in Figure 1. A total of 14 studies examined the association between the SULT1A1 R213H polymorphism and CRC [11–24]. Of these, 2 were excluded (the data of 1 study was unavailable, 1

Table 1. Characteristics of studies included in the meta-analysis.*

| ID  | Study          | Year | Ethnic group   | Sample size (Frequency of H allele, %) | OR (95% CI) for H versus R allele | Hardy-Weinberg equilibrium of genotype of control |
|-----|----------------|------|----------------|---------------------------------------|----------------------------------|-----------------------------------------------|
| 1   | Cotterchio et al. [11] | 2008 | mainly Caucasian | 834(31.35) 1249(32.78) | 0.936(0.820–1.070) | 0.078 |
| 2   | Lilla et al. [12] | 2007 | Caucasian | 504(35.61) 603(34.91) | 1.031(0.866–1.229) | 0.178 |
| 3   | Chen et al. [13] | 2006 | Asian | 140(8.93) 343(6.27) | 1.466(0.877–2.451) | 0.749 |
| 4   | Gaustadnes et al. [14] | 2006 | Caucasian | 230(37.39) 540(32.69) | 1.230(0.980–1.544) | NA |
| 5   | Sun et al. [15] | 2005 | Caucasian | 109(48.17) 666(37.31) | 1.561(1.171–2.082) | 0.478 |
| 6   | Landi et al. [16] | 2005 | Caucasian | 361(26.59) 320(26.88) | 0.986(0.775–1.254) | 0.011 |
| 7   | Sterjev et al. [17] | 2005 | Caucasian | 100(27.00) 200(34.91) | 0.637(0.439–0.924) | 0.034 |
| 8   | Pereira et al. [18] | 2005 | Brazilian | 42(36.90) 100(33.00) | 1.188(0.897–2.022) | 0.960 |
| 9   | Sachse et al. [19] | 2002 | Caucasian | 490(34.39) 593(32.12) | 1.107(0.925–1.325) | 0.734 |
| 10  | Nowell et al. [20] | 2002 | Caucasian | 130(37.31) 301(42.36) | 0.801(0.601–1.092) | 0.815 |
| 11  | Wong et al. [21] | 2002 | Caucasian | 383(34.51) 402(32.08) | 1.116(0.860–1.447) | 0.621 |
| 12  | Bamber et al. [22] | 2001 | Caucasian | 226(34.51) 293(32.08) | 1.116(0.860–1.447) | 0.621 |

*OR: odds ratio; CI: confidence interval; NA: not available.
doi:10.1371/journal.pone.0019127.t001
was duplicate report) [23,24]. Thus, 12 studies were included in the current meta-analysis [11–22].

12 studies consisted of 10 Caucasian, 1 Asian and 1 Brazilian. The allele and the genotype frequencies of the SULT1A1 R213H polymorphism were extracted from 11 studies. But only allele frequency was extracted from the study by Gaustadnes et al. [14]. Therefore, examining the contrast of HH versus RR, HR versus RR, HR+HH versus RR, and HH versus RR+HR, the meta-analysis was performed with 11 studies overall, and 9 studies Caucasian. Examining the contrast of H allele versus R allele, meta-analysis was performed with 12 studies overall, and 10 studies Caucasian.

The results of HWE test for the distribution of the genotype in control population are shown in Table 1. Two studies were not in HWE in eligible studies [16,17]. It was unavailable for one study to perform HWE test [14].

Meta-analysis

The main results of this meta-analysis and the heterogeneity test are shown in Table 2.

Analysis in overall population

The association between the SULT1A1 R213H polymorphism and CRC was investigated in 12 studies with a total of 3,549 cases and 5,610 controls. We detected significant between-study heterogeneity in the contrasts of H versus R, HH versus RR+HR, and HH versus RR. We found no association between the SULT1A1 R213H polymorphism and CRC in overall population (H versus R: OR = 1.04, 95%CI = 0.94–1.16, P = 0.46; HR+HH versus RR: OR = 1.01, 95%CI = 0.92–1.11, P = 0.81; HH versus RR+HR: OR = 1.01, 95%CI = 0.74–1.38, P = 0.95; HH versus RR: OR = 1.00, 95%CI = 0.77–1.31, P = 0.98; HR versus RR: OR = 1.01, 95%CI = 0.92–1.11, P = 0.86).

Analysis in HWE population

Meta-analysis was carried out in those studies fulfilling HWE. The meta-analysis included 9 studies (2,858 cases and 4,550 controls). The Q-test of heterogeneity was significant in the contrasts of H versus R, HH versus RR+HR, and HH versus RR. We did not detect an association of the SULT1A1 R213H polymorphism and CRC in HWE population (H versus R: OR = 1.06, 95%CI = 0.95–1.19, P = 0.31; HR+HH versus RR: OR = 1.03, 95%CI = 0.93–1.13, P = 0.56; HH versus RR+HR: OR = 1.10, 95%CI = 0.78–1.56, P = 0.57; HH versus RR: OR = 1.09, 95%CI = 0.93–1.44, P = 0.53; HR versus RR: OR = 1.02, 95%CI = 0.92–1.13, P = 0.75).

Analysis in Caucasian population

The meta-analysis included 10 studies (3,367 cases and 5,167 controls) in Caucasian population. The Q-test of heterogeneity was significant in the contrasts of H versus R, HH versus RR+HR, and HH versus RR. No statistically significant association was established for the SULT1A1 R213H polymorphism in Caucasian population (H versus R: OR = 1.02, 95%CI = 0.92–1.15, P = 0.68; HR+HH versus RR: OR = 0.99, 95%CI = 0.91–1.09, P = 0.90; HH versus RR+HR: OR = 1.01, 95%CI = 0.73–1.39, P = 0.97; HH versus RR: OR = 0.99, 95%CI = 0.75–1.31, P = 0.94; HR versus RR: OR = 0.99, 95%CI = 0.90–1.09, P = 0.85).

Evaluation of publication bias

The shapes of the funnel plots did not reveal any evidence of obvious asymmetry (funnel plots not shown). Meanwhile, we...
assessed funnel plot asymmetry by the method of Egger’s linear regression test. The intercept \(a\) provides a measure of asymmetry, and the larger its deviation from zero the more pronounced the asymmetry. The results of Egger’s linear regression test are shown in Table 3. It was shown that there was no publication bias for all comparisons. Moreover, the results were not materially altered after the studies which did not fulfill HWE were excluded. Our meta-analysis suggests that the SULT1A1 R213H polymorphism is not associated with CRC development. As far as we know, this is the first meta-analysis carried out so far aimed at investigating the association of the SULT1A1 R213H polymorphism with CRC.

SULT1A1 are associated with the detoxification and activation of different carcinogens, and the regulation of many hormones [7,8]. It has been observed that a G to A transition at nucleotide 638 in SULT1A1 gene causes an Arg to His substitution associated with low enzymatic activity [10]. Recently, studies have suggested that SULT1A1 HH genotype was associated with an increased risk for some cancers development, such as esophagus, breast, and lung cancer [33–35]. These results seem to support that low activity of SULT1A1*H allozyme lacks a protection against dietary and/or environmental chemicals involved in the carcinogenesis of cancer. However, our meta-analysis suggests that the SULT1A1 R213H polymorphism is not associated with CRC risk. The study by Rafiqianis et al. [10] suggests that this polymorphism is associated with a low enzyme activity. The enzyme activity was measured using platelet preparations in this study. Nevertheless, the use of platelets to determine the activity of a specific enzyme can be misinterpreted due to the inability of the

**Table 2.** Meta-analysis of the association of SULT1A1 R213H polymorphism and colorectal cancer.*

| Polymorphism | Study | Sample size | No. of Studies | Test of association | Test of heterogeneity |
|--------------|-------|-------------|----------------|---------------------|----------------------|
|              |       | Case | Control | OR (95%CI) | Z   | P-value | Model | I² | P-value | I² (%) |
| H vs R Overall | 7098 | 11220 | 12 | 1.04(0.94–1.16) | 0.75 | 0.46 | R | 25.00 | 0.009 | 56.0 |
| HWE | 5716 | 9000 | 9 | 1.06(0.95–1.19) | 1.01 | 0.31 | R | 16.13 | 0.04 | 50.4 |
| Caucasian | 6734 | 10334 | 10 | 1.02(0.92–1.15) | 0.41 | 0.68 | R | 22.83 | 0.007 | 60.6 |
| HR+HH vs RR Overall | 3319 | 5070 | 11 | 1.01(0.92–1.11) | 0.24 | 0.81 | F | 8.53 | 0.58 | 0.0 |
| HWE | 2858 | 4550 | 9 | 1.03(0.93–1.13) | 0.58 | 0.56 | F | 5.31 | 0.72 | 0.0 |
| Caucasian | 3137 | 4627 | 9 | 0.99(0.91–1.09) | 0.12 | 0.90 | F | 5.53 | 0.70 | 0.0 |
| HH vs RR+HR Overall | 3319 | 5070 | 11 | 1.01(0.74–1.38) | 0.07 | 0.95 | R | 37.81 | <0.0001 | 73.6 |
| HWE | 2858 | 4550 | 9 | 1.10(0.78–1.56) | 0.57 | 0.57 | R | 32.46 | <0.0001 | 75.4 |
| Caucasian | 3137 | 4627 | 9 | 1.01(0.73–1.39) | 0.04 | 0.97 | R | 37.34 | <0.0001 | 78.6 |
| HH vs RR Overall | 1945 | 2999 | 11 | 1.00(0.77–1.31) | 0.03 | 0.98 | R | 25.00 | 0.005 | 60.0 |
| HWE | 1648 | 2666 | 9 | 1.09(0.83–1.44) | 0.62 | 0.53 | R | 19.24 | 0.01 | 58.4 |
| Caucasian | 1809 | 2641 | 9 | 0.99(0.75–1.31) | 0.07 | 0.94 | R | 24.55 | 0.002 | 67.4 |
| HR vs RR Overall | 2948 | 4482 | 11 | 1.01(0.92–1.11) | 0.18 | 0.86 | F | 10.75 | 0.38 | 6.9 |
| HWE | 2528 | 4028 | 9 | 1.02(0.92–1.13) | 0.32 | 0.75 | F | 9.68 | 0.29 | 17.3 |
| Caucasian | 2771 | 4051 | 9 | 0.99(0.90–1.09) | 0.19 | 0.85 | F | 7.68 | 0.46 | 0.0 |

*HWE: Hardy-Weinberg equilibrium.

**Table 3.** Egger’s linear regression test to measure the funnel plot asymmetric.*

| Comparisons | Y axis intercept: a (95%CI) |
|-------------|-----------------------------|
| H vs R | 0.75(–2.03 to 3.55) |
| HR+HH vs RR | 0.48(–1.29 to 2.25) |
| HH vs RR+HR | –0.30(–3.66 to 3.04) |
| HH vs RR | –0.13(–2.87 to 2.60) |
| HR vs RR | 0.04(–1.96 to 2.05) |

*HWE: Hardy-Weinberg equilibrium.

**Discussion**

Multiple lines of evidence support an important role for genetics in determining risk for cancer, and association studies are appropriate for searching susceptibility genes involved in cancer [31]. Nevertheless, small sample sized association studies lack statistical power and have resulted in apparently contradicting findings [32]. Meta-analysis is a means of increasing the effective sample size under investigation through the pooling of data from individual association studies, thus enhancing the statistical power of the analysis for the estimation of genetic effects [25]. In the current meta-analysis, on the basis of 12 case-control studies providing data on the SULT1A1 R213H polymorphism and CRC involving 3,549 cases and 5,610 controls, we did not find any significant association between the SULT1A1 R213H polymorphism and CRC among overall and Caucasian populations.

Moreover, the results were not materially altered after the studies which did not fulfill HWE were excluded. Our meta-analysis suggests that the SULT1A1 R213H polymorphism is not associated with CRC development. As far as we know, this is the first meta-analysis carried out so far aimed at investigating the association of the SULT1A1 R213H polymorphism with CRC. SULT1A1 are associated with the detoxification and activation of different carcinogens, and the regulation of many hormones [7,8]. It has been observed that a G to A transition at nucleotide 638 in SULT1A1 gene causes an Arg to His substitution associated with a low enzymatic activity [10]. Recently, studies have suggested that SULT1A1 HH genotype was associated with an increased risk for some cancers development, such as esophagus, breast, and lung cancer [33–35]. These results seem to support that low activity of SULT1A1*H allozyme lacks a protection against dietary and/or environmental chemicals involved in the carcinogenesis of cancer. However, our meta-analysis suggests that the SULT1A1 R213H polymorphism is not associated with CRC risk. The study by Rafiqianis et al. [10] suggests that this polymorphism is associated with a low enzyme activity. The enzyme activity was measured using platelet preparations in this study. Nevertheless, the use of platelets to determine the activity of a specific enzyme can be misinterpreted due to the inability of the

**Table 3.** Egger’s linear regression test to measure the funnel plot asymmetric.*

| Comparisons | Y axis intercept: a (95%CI) |
|-------------|-----------------------------|
| H vs R | 0.75(–2.03 to 3.55) |
| HR+HH vs RR | 0.48(–1.29 to 2.25) |
| HH vs RR+HR | –0.30(–3.66 to 3.04) |
| HH vs RR | –0.13(–2.87 to 2.60) |
| HR vs RR | 0.04(–1.96 to 2.05) |

*P > 0.05; vs: versus; HWE: Hardy-Weinberg equilibrium.

doi:10.1371/journal.pone.0019127.t003

doi:10.1371/journal.pone.0019127.t002
method to distinguish which enzyme is responsible for the activity observed [21]. Moreover, preliminary modelling studies indicate that this polymorphism does not appear to directly affect the binding site of the substrate or of the universal sulphonate donor 3′-phosphoadenosine-5′-phosphosulphate (PAPS) [36]. Meanwhile, futher the study performed by Ozawa et al. [37], although a recombiant enzyme was used, differences in sulphonating abilities were only slight, which may be explained by the compromise in thermostability the amino acid change causes. In addition, evidences suggest that the SULT1A1 R213H polymorphism is in linkage disequilibrium with SULT1A2 N235T [38,39]. Thus, it is possible that the activity measured in their study is attributable to SULT1A2 and SULT1A1. Further studies of the functional implications of this polymorphism are still needed in the future.

Several specific details merit consideration in the current meta-analysis. Firstly, a recent meta-analysis showed that the SULT1A1 R213H polymorphism had no exact effect to increase the risk of breast cancer, but it did increase the risk of breast cancer among postmenopausal women [40]. Therefore, this polymorphism may only play a role in conjunction with environmental exposures. A more precise analysis stratified by environmental exposures could be performed if individual data were available. Secondly, it is worth mentioning that only 2 of the 12 studies were conducted in non-Cauasian population in our meta-analysis. Hence, the results of our meta-analysis indicate that there is no association between the SULT1A1 R213H polymorphism and CRC, mainly in Cauasian population. Thirdly, significant between-study heterogeneity was detected in some comparisons, and may be distorting the meta-analysis. Fourthly, only published studies were included in this meta-analysis, and publication bias may occur. Fifthly, our results should be interpreted with caution because the prevalence of the SULT1A1 R213H polymorphism may be different in various subtypes of CRC. A analysis stratified by different subtypes of CRC may provide a more precise result. Finally, although we minimized the likelihood of bias by developing a detailed protocol before initiating the study, meta-analysis remains retrospective research that is subject to the methodological deficiencies of the included studies.

In conclusion, our meta-analysis demonstrates that there is no association between the SULT1A1 R213H polymorphism and CRC, mainly in Cauasian population. To reach a definitive conclusion, further gene-gene and gene-environment interactions studies based on larger sample size are still needed, especially in non-Cauasian population.

Supporting Information
Checklist S1
(DOC)

Acknowledgments
We thank everyone who helped with this study.

Author Contributions
Conceived and designed the experiments: CZ JPL PZ. Performed the experiments: CZ GQL XMY YLG JPL PZ. Analyzed the data: CZ GQL XMY YLG. Wrote the first draft of the paper: CZ. Contributed to the writing of the paper: CZ JPL PZ. Approved manuscript’s results and conclusions: CZ GQL XMY YLG JPL PZ. Responsible for data integrity: PZ. Principal investigator for the study: CZ.

References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
2. Jemal A, Siegel R, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. (2000) Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Eng J Med 343: 78–85.
4. Coughtrie MW (2002) Sulfation through the looking glass–recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2: 297–309.
5. Harris RM, Pietro R, Singh S, Waring RH (2000) Activity of phenol sulfotransferases in the human gastrointestinal tract. Life Sci 67: 2051–2057.
6. Chou HC, Lang NP, Kadlubar FF (1995) Metabolic activation of N-hydroxy arylamines and N-hydroxy-heterocyclic amines by human sulfotransferase(s). Cancer Res 55: 525–529.
7. Glatt H (1997) Sulfation and sulfotransferases 4: bioactivation of mutagens via sulfation. FASEB J 11: 314–321.
8. Glatt H (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129: 141–170.
9. Dooley TP, Obermeower RD, Leiter EH, Chapman HD, Falany CN, et al. (1995) Mapping of the phenol sulfotransferase gene (SFT) to human chromosome 16p12-p11.2 and to mouse chromosome 7. Genomics 18: 440–443.
10. Raftogianis RB, Wood TC, Ottemer DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239: 298–304.
11. Cotterchio M, Boucher BA, Mannino M, Gallinger S, Okey AB, et al. (2008) Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 3098–3107.
12.etta L, Risch A, Verla-Tebit E, Hoffmeister M, Brenner H, et al. (2007) SULT1A1 genotype and susceptibility to colorectal cancer. Int J Cancer 120: 205–209.
13. Chen K, Fan CH, Jin MJ, Song I, Xu H, et al. (2006) A case-control study on the association between the genetic polymorphism of sulfotransferase 1A1, diet and susceptibility of colorectal cancer. Zhonghua Zhong Liu Za Zhi 28: 670–673.
14. Gaustadnes M, Ormøtt TF, Jensen JL, Torring N (2006) Validation of the use of DNA pools and primer extension in association studies of sporadic colorectal cancer for selection of candidate SNPs. Hum Mutat 27: 187–194.
15. Sun XF, Ahmadi A, Ashman G, Wallin A, Aukid D, et al. (2005) Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase PI genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 11: 6673–6679.
16. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, et al. (2005) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15: 533–546.
17. Sertaj B, Josifovski T, Panowski M, Sutarkova L, Dimovski AJ (2003) The SULT1A1 allele with low potential for estrogen inactivation is associated with reduced colorectal cancer risk in postmenopausal women. Balkan J Med Genet 8: 43–48.
18. Pereira WO, Paiva AS, Queiroz JW, Toma I, Dietrich CP, et al. (2005) Genetic polymorphism in the sulfotransferase SULT1A1 gene in cancer. Cancer Genet Cytoenet 160: 55–60.
19. Sache S, Smith G, Wilkie MJ, Barrett JH, Waxman R, et al. (2002) A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839–1849.
20. Nowell S, Coles B, Sinha R, MacLeod S, Luke Ramaosinghe D, et al. (2002) Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. Mutat Res 506–507: 175–183.
21. Wong CF, Liyou N, Leggett B, Young J, Johnson A, et al. (2002) Association of the SULT1A1 R213H polymorphism with colorectal cancer. Clin Exp Pharmacol Physiol 29: 754–758.
22. Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, et al. (2001) Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced colorectal cancer risk in postmenopausal women. Int J Cancer 94: 84–89.
23. Sun XF, Ahmadi A, Ashman G, Wallin A, Aukid D, et al. (2005) Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase PI genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 11: 6673–6679.
24. Moreno V, Glatt H, Guino E, Fisher E, Meinl W, et al. (2005) Polymorphisms in sulfotransferase SULT1A1*1 genotype is associated with reduced colorectal cancer risk in postmenopausal women. Int J Cancer 120: 205–209.
25. Munafo MR, Flint J (2004) Meta-analysis of genetic association studies. Trends Genet 20: 438–444.
26. Cochrane WG (1958) The combination of estimates from different experiments. Biometrics 10: 101–129.
27. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
28. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177–188.
30. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Br Med J 315: 629–634.
31. Risch N, Merikangas K (1996) The future of genetic studies of complex human diseases. Science 273: 1516–1517.
32. Lohmueller KE, Pearce CH, Pike M, Laird ES, Hirschhorn JN (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177–182.
33. Wu MT, Wang YT, Ho CK, Wu DC, Lee YC, et al. (2003) SULT1A1 polymorphism and esophageal cancer in males. Int J Cancer 103: 101–104.
34. Han DF, Zhou X, Hu MB, Wang CH, Xie W, et al. (2004) Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women. Toxicol Lett 150: 167–177.
35. Liang G, Miao X, Zhou Y, Tan W, Lin D (2004) A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis 25: 773–778.
36. Bidwell LM, McManus ME, Gaedigk A, Kakuta Y, Negishi M, et al. (1999) Crystal structure of human catecholamine sulfotransferase. J Mol Biol 293: 521–530.
37. Ozawa S, Shimizu M, Katoh T, Miyajima A, Ohno Y, et al. (1999) Sulfitating activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 ([213]Arg) and ST1A3*2 ([213]His), both of which exist in Japanese as well as Caucasians. J Biochem 126: 271–277.
38. Nowell S, Ambrosone CB, Ozawa S, MacLeod SL, Mrackova G, et al. (2000) Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics 10: 789–797.
39. Engelke CE, Meinl W, Boring H, Glatt H (2000) Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 10: 163–169.
40. Jiang Y, Zhou L, Yan T, Shen Z, Shao Z, et al. (2010) Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal stases. J Exp Clin Cancer Res 29: 101.